Prosecution Insights
Last updated: November 20, 2026

Erica Nicole Jones-Foster, USPTO Patent Examiner

Listed by the USPTO as JONES-FOSTER, ERICA NICOLE

Tech Center 1600 • Art Units: 1612 1644 1655 1656

This examiner grants 50% of resolved cases

Analysis

JONES-FOSTER, ERICA NICOLE works in tech center 1600 and art unit 1612. Her record includes 91 resolved cases and a 50.5% allowance rate. The median time to allowance is 1281 days, indicating that applicants should plan for extended prosecution even though the outcome is close to an even split.

The interview lift is 37.7%. That association makes interviews a potentially useful tool for testing claim distinctions and narrowing disputes. Counsel should approach an interview with a specific resolution proposal and follow it with amendments or written clarification where appropriate.

The listed companies are Merck Sharp & Dohme LLC, Novozymes A/S, and Hanmi Pharm. Co., Ltd. The listed firms are MAIER & MAIER, PLLC, SUGHRUE MION, PLLC, and ARENTFOX SCHIFF LLP. These names provide context for recurring pharmaceutical applicants and representatives in the profile.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

50.5%
Allow Rate
-9.5% vs TC avg
162
Total Applications
+37.7%
Interview Lift
1281
Avg Prosecution Days
Based on 91 resolved cases, 2023–2026

Rejection Statute Breakdown

8.2%
§101 Eligibility
20.4%
§102 Novelty
37.8%
§103 Obviousness
24.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17185196 GENETICALLY MODIFIED BACTERIAL CELLS AND METHODS USEFUL FOR PRODUCING TETRAMETHYL PYRAZINE Final Rejection The Regents of the University of California
17267816 DESIGNED, EFFICIENT AND BROAD-SPECIFICITY ORGANOPHOSPHATE HYDROLASES Final Rejection Yeda Research and Development Co. Ltd.
17437232 MICROBIAL TEST KIT, MICROBIAL TEST METHOD AND MICROBIAL TEST DEVICE Non-Final OA HITACHI HIGH-TECH CORPORATION
17795939 COMPOSITIONS COMPRISING LINEAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF Non-Final OA Flagship Pioneering Innovations VI, LLC
17040448 DEVICE FOR MANUFACTURING ORGANIC SUBSTANCE, AND GAS PROCESSING SYSTEM Final Rejection SEKISUI CHEMICAL CO., LTD.
18031313 CRISPR/CAS-BASED BASE EDITING COMPOSITION FOR RESTORING DYSTROPHIN FUNCTION Final Rejection Duke University
18245872 GENERATION OF A HIGH PRODUCING RECOMBINANT CHINESE HAMSTER OVARY CELL LINE FOR THERAPEUTIC PROTEIN PRODUCTION Final Rejection SANOFI
17299273 Powder Detergent Compositions Non-Final OA Novozymes A/S
18516310 P450-BM3 VARIANTS WITH IMPROVED ACTIVITY Non-Final OA Codexis, Inc.
18578581 RECOMBINANT YEAST CELL Final Rejection DANISCO US INC.
17792670 CONSORTIA OF MICROORGANISMS FOR SPATIAL AND TEMPORAL DELIVERY OF NITROGEN Final Rejection Pivot Bio, Inc.
18030476 METHODS AND COMPOSITIONS COMPRISING PD1 CHIMERIC POLYPEPTIDES Non-Final OA Seattle Children's Hospital (dba Seattle Children's Research Institute)
18036580 USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF RENAL DISEASES CAUSED BY OR ACCOMPANIED BY FABRY DISEASE Final Rejection HANMI PHARM. CO., LTD.
18036538 USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF NEUROPATHY CAUSED BY OR ACCOMPANIED BY FABRY DISEASE Final Rejection HANMI PHARM. CO., LTD.
18562092 A METHOD OF SEPARATING BISPECIFIC ANTIBODIES Non-Final OA Cytiva BioProcess R&D AB
17945293 PROBIOTICS FOR USE IN REDUCING THE INCIDENCE AND DURATION OF ILLNESS Final Rejection DUPONT NUTRITION BIOSCIENCES APS
18534574 BIOLOGICAL ENZYME FOR KILLING VIRUSES AND PREPARATION METHOD THEREOF Final Rejection Changde Jizhi Biological Technology Co., Ltd

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Erica Nicole Jones-Foster's allowance rate?

50.5% of resolved applications examined by Erica Nicole Jones-Foster were allowed (91 resolved cases), compared with 40.6% across Art Unit 1612 over the last five years.

Does an interview help with examiner Erica Nicole Jones-Foster?

This examiner's interview lift is +37.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Erica Nicole Jones-Foster take to allow a patent?

Applications allowed by Erica Nicole Jones-Foster took 1,281 days on average from filing to allowance.

Which art unit does examiner Erica Nicole Jones-Foster work in?

Erica Nicole Jones-Foster examines applications in Art Unit 1612 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month